Home

Welcome to VitroVivo Biotech

Products

Services

  • Laser Capture Microdissection (LCM)
  • Routine Paraffin Histology
  • Cryotomy (Frozen Sectioning )
  • Special Staining
  • Specialized Histology
  • Molecular Histopathology
  • Customized Biospecimen Collection for Biomedical Research
  • FFPE, Frozen and LCM Sample Analysis
  • Histopathology Images and Analysis Services
  • Slide Review by Board Certified Pathologist

For More Information, click here>>>

Histopathology and Laser Capture Microdissection Services

About Us

VitroVivo Biotech is a company engaged in the development and commercialization of the innovation histological products and services. The company was founded by a group of biomedical scientists in 2012 and is located in Rockville of the I-270 corridor of Montgomery County, Maryland.

The mission of our company is to use our expertise in histology and molecular histopathology to help the scientists from biomedical research institutions and biotechnological enterprises or pharmaceutical companies to accelerate their discovery. VitroVivo is committed to its mission to “make tissues, cells, genes and molecules visible

Equipped with state-of-the-art technology and devices, we at VitroVivo are able to provide full-scale histology and molecular histopathology services, including tissue processing, embedding, sectioning, histochemical staining, immunostaininng, FISH/ISH and expert evaluation by our certified pathologists. Besides, our laser capture microdissection (LCM) services offer our customers an opportunity to enjoy more power, precision and effectiveness in isolating specific cells from a heterogeneous cell population under microscopic visualization for gene expression analysis and other biomedical study purposes. Our service team includes leading international experts on LCM, board-certified pathologists and molecular histopathology experts. 

VitroVivo Biotech has nine product categories for histology staining kits, molecular histopathology kits and reagents available for purchase. The product distribution covers not only the US but also Europe and Asia-Pacific regions.

Major clients and customers VitroVivo has proudly fulfilled orders for include many labs of the National Institute of Health (NIH), prominent research institutions, universities, biotechnological companies and pharmaceutical companies.

Our Lab Facility

   
   

Selected Clients from USA

(Click on the logo to be linked to the institution or company)​

National Institutes of Health

Georgetown University

U.S. Naval Research Lab

Wayne State University 

Emory University

The University of California, Los Angeles

Duke University

Stanford University

University of Denver

Johns Hopkins University

Washington University in St. Louis

University of Maryland
  The Feinstein Institute for Medical Research  

Selected Publications Citing VitroVivo’s Services and Products from the Recent literature

  • Soontarapornchai K, et al (2021). Pharmacodynamic Effects of Standard versus High Caffeine Doses in the Developing Brain of Neonatal Rats Exposed to Intermittent Hypoxia. Int. J. Mol. Sci. , 22(7), 3473
  • Lee CL, et al (2021). Characterization of cardiovascular injury in mice following partial-heart irradiation with clinically relevant dose and fractionation. Radiotherapy and Oncology.157:155-162
  • Manlapaz-Mann A, et al (2021). Effects of omega 3 polyunsaturated fatty acids, antioxidants, and/or non-steroidal inflammatory drugs in the brain of neonatal rats exposed to intermittent hypoxia. Intl J Dev Neuroscience. First published: 09 May 2021, https://doi.org/10.1002/jdn.10120
  • Ko KW, et al (2021) . integrated Bioactive Scaffold with Polydeoxyribonucleotide and Stem-Cell-Derived Extracellular Vesicles for Kidney Regeneration. ACS Nano; 15, 4, 7575–7585
  • Tropea MR, et al (2021). A failure of β-amyloid physiological function due to genetic deletion of α7 nicotinic acetylcholine receptors induces an Alzheimer’s disease-like pathology, BioRxiv. https://doi.org/10.1101/2021.01.05.425382
  • Han Y, et al (2020).Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature; 589 (2021), 270–275.
  • Diana M, et al (2020). Allograft inflammatory factor-1 in myeloid cells drives autoimmunity in type 1 diabetes. JCI Insight. 5(10): e136092.
  • Kawakami M, et al (2020). A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis and Metastasis in Aneuploid Cancers. Mol Cancer Ther. 2020 Dec 4;molcanther.0987.2019. doi: 10.1158/1535-7163.MCT-19-0987.
  • Wu B, et al. (2020). Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation. J Immunother Cancer. 8(2): e000964.
  • Shen DF, et al.(2020). Astaxanthin suppresses endoplasmic reticulum stress and protects against neuron damage in Parkinson’s disease by regulating miR-7/SNCA axis. Neurosci Res. S0168-0102(20)30018-3.
  • Chen J, et al. (2020). Conventional Co-Housing Modulates Murine Gut Microbiota and Hematopoietic Gene Expression.Int. J. Mol. Sci. 21(17), 6143;
  • Diana M, et al. (2020). Allograft inflammatory factor-1 in myeloid cells drives autoimmunity in type 1 diabetes. JCI Insight.  5(10): e136092.
  • Li J, et al. (2020). Attenuation of immune‐mediated bone marrow damage in conventionally housed mice. Molecular Carcinogenesis, 59 (2), 237-245
  • Luca ME, et al. (2019). Genetic deletion of syndecan-4 alters body composition, metabolic phenotypes, and the function of metabolic tissues in female mice fed a high-fat diet. Nutrients 11(11), 2810.
  • Daxesh P,  et al. (2019). Withaferin a Improves nonalcoholic steatohepatitis in mice. Journal of Pharmacology and Experimental Therapeutics. 371 (2) 360-374
  • Zhang CK, et al.(2018) Long-term In vitro expansion of epithelial stem cells enabled by pharmacological inhibition of PAK1-ROCK-Myosin II and TGF-β signaling. Cell Report,25(3), 598-610.e5
  • Hollinger MK, et al. (2018). PD-1 deficiency augments bone marrow failure in a minor-histocompatibility antigen mismatch lymphocyte infusion model. Experimental Hematology. 62, 17-23